Oxford BioMedica Live Stream

Stream Discuss Polls Ratings Documents

d gaser 15 Sep 2017

Director buys 100.000 shares @8.10p Its good to see Martin buying more shares it's just a pity some of the others don't follow his lead ,RNS 15.09.2017Martin Diggle, Non Executive Director, bought 100,000 shares in the company on the 14th September 2017 at a price of 8.10p. The Director now holds 549,932,000 shares.BE HAPPYDav

MaX ProfOrdiS 14 Sep 2017

Re: Sell: Bearish Charts To clarify. If there had been an immediate sell off following the announcements I could have understood that; buy on rumour sell on news. What bamboozles me is that there wasn't an immeidate sell off. There was real, if but too briefly, demand until the MMs stepped in and shut the market down (the MMs tied up the market in auctions until they'd rested back control and were able to move the price down). I can't ever recollect seeing that before.

MaX ProfOrdiS 14 Sep 2017

Re: Sell: Bearish Charts They will eventually; a share offer out of the blue would probably turn your charts upside down.But, back in the real world, you do appear to have called it right this time.I know they say buy on rumour sell on news but I am still perplexed by the share price action on the day of both announcements (the recommendation and the approval). Most bizarre; generally PI enthusiasm is allowed to run its course before the MMs step in but the way they stepped in and killed any momentum was brutal. Was it simply because there was a large seller or something more to it.I'm sticking for the time being. It will probably cost me but I'm irked!

Trouble_Two 14 Sep 2017

Re: Sell: Bearish Charts The charts have never let me down.13 Sep 2017DAILY8.19 Triple Moving Average Crossover (4-day 9-day 18-day) 11 Sep 2017DAILY8.71 Momentum 08 Sep 2017DAILY8.82 Double Moving Average Crossover (21-day 50-day) 08 Sep 2017WEEKLY8.82 Relative Strength Index (RSI) TTGLAH

mol42 12 Sep 2017

Hardman 120917 not in here but noted this today[link]

d gaser 08 Sep 2017

Gene therapy fantasy deal not realistic ? pharmaspecialist  I thought I should just let you know OXB all ready has a US Nasdaq listing, it goes' under Oxford Biomedica (NASDAQ:OXBDF) So any listing by Nightstar Therapeutics wouldn't help OXB , unless of course a deal could be done prior to them listing ,in which case, they would lose out on the £65m they are raising via that I.P.O. As we know from our own experience that cash won't get them to their end stage 4, especially if they don't have FDA approval for their AAV2 vector and manufacturing facilities, and would also need to get same clearance for the recombinant human complementary DNA they use before the FDA would give them a licence .Where as Novartis, Sanofi Aventis , Pfizer , and GSK and our self's all ready have a licence for production of the vector ,and DNA products,so why would OXB want to give a potential rival access to their technology for free?.Remember it will take years before Nightstar get any thing to market, by which time, most of the big Bio 4 companies will have got their own retinal disease products to market, as there is a big race going on right now to see who can capture that this massif market,especially for the wet &Dry Macular disease, and for retinitis pigmentosa market.Personally I don't see any incentives for OXB or Novartis, or any other company come to that, who are all ready involved in this science to buy out nightstar, unless of course they have some excellent intellectual property, or other science that others don't have, and if that is the case, then it's normal practice for such companies' to licence out that technology as it would generate their only means of income ,which in nightstars case, would be crucial to their survival over the next 5-10 years I would of thought, just as it has been for OXB over the last 20 years .Maybe one of the big boys might take them out in order to obtain the cash ,but I don't see how OXB could amalgamate with them, unless they formed a new company with new stock ,or OXB reversed in to Nighthawk ,and then cancel OXB 3billion plus shares they have, and then re rate Night hawk shares prorate .just my personal thoughts on this subject so .P.D.Y.HBE HAPPYDAVE

MaX ProfOrdiS 08 Sep 2017

Despite ... ... the bearish charts, I'm going to put my neck out and say that I do believe that OXB may have turned this morning.Somebody was in first thing to pick up 500,000 at 9.0327 and the bid/offer spread is now edging up.I saw yesterday's RNS that Joy Group have recently disposed of 30m shares, which might explain the "strange" price movements over the last month.

S17 07 Sep 2017

Re: Marketing Authority is next line That's the trouble with this share. Too few buyers understand the science and the long lead time from initial research, to discovery, careful testing, further development with other companies, to production, to selling enough to make a profit. All the talk of charts and MMs is fine, but the fundamental issue is how well all the above can be managed along with the cash burn until substantial and reliable revenues can flow in. Almost 20 years ago I wrote of taking a 10 year view and was told I was too pessimistic. I warned that speculators would make, and lose along the way, but the MMs would always ensure they won. Dead right I've been. I still think we may need to look beyond a year or two, and 5 years is a more reasonable timescale before we'll know which way this is going.In 5 years we could have failed entirely, been taken over, or the SP may be 5, 10 or 50 times higher. I wrote off such hopes many years ago, but wouldn't mind if that did eventually happen - although 50x won't! In all probability we'll be tottering along, hand to mouth, still looking forward to jam tomorow.In the meantime I'm happy that OXB is developing science that may one day lead to treatments to benefit future generations.

d gaser 07 Sep 2017

Marketing Authority is next line Just because we have FDA approval it doesn't mean we can start production and the market knows this ,it can take another 6 months be fore Novartis will gain marketing approval ,and this includes pre production testing to ensure the product is safe once the manufacturing lines start.It could take another 3 months from that date before the product is offered to the likes of N.I.C.E ,or the U.S.A or European agencies' ,or any other countries agencies, the product will go through scrutiny and price negotiations before they can even think about selling it ,in all, it could be another year to eighteen months before any country agree to use it ,but there again, they could accept the product with in 6 months if the price is right, and they can prove the procedure will help them make savings but even then they would have to train the doctors on how to use it ..This time gap is probably why the price is now falling back again, what happens next lie's with the individual countries health authorities,and how quick this procedure is taken up and marketed .PDYH BE HAPPYDAVE

Trouble_Two 07 Sep 2017

Re: Sell: Bearish Charts MaxThis news is not helping the Novartis or OXB share prices, it should because it lengthens the time where we have the market, but I guess investors do not know the difference between our CAR-T treatment and an allogeneic CAR-T. Since the "good news" this share has gone from 11p to 8.8p. SP support around 6p. Maybe I should stay away from shares that I don't understand (i.e. HEALTH). If I look at the performance of this share since the "good news", then I am really confused and lost faith (even with 25 years of trading). But as always DYOR and GL.TT

MaX ProfOrdiS 07 Sep 2017

Re: Sell: Bearish Charts That's a buy signal in my books; Trouble-Two has been a 100% wrong thus far! Only joking!Still mulling this one nd trying to make sense of the recent price movements.

pharmaspecialist 07 Sep 2017

Gene therapy fantasy deal? Am I being too optimistic or could there be a chance of creating one of the world's leading gene therapy companies by merging OXB with another Oxford University spin-off, Nightstar Therapeutics? Nightstar is undergoing an IPO on Nasdaq hoping to raising £65m for further clinical development , having raised £34M privately in July 2017. A merger would reduce risk by adding diversity to the resulting company as Nightstar uses a different viral vector system to OXB. I am sure OXB's regulatory experience and bioprocessing expertise would come in useful for Nightstar which, like OXB, includes two products in clinical trials for eye disorders. There surely must be some synergy there. Nightstar would also gain a ready made marketing partner (Novartis) and funding raised for a potential merger would enable OXB to develop its wholly owned product candidates a bit further to the point where it could get decent royalties through partnership deals. This would also fit in with the philosophy of Nightstar's major shareholder, Syncona, of it reaping the full rewards of biotechnology developed in the UK academic sector. You may ask why Nightstar hasn't already merged with OXB, well I am sure the US is the right place for OXB to list so Nightstar's ability to raise funds and get a US listing before a takeover/merger with OXB is not necessarily silly. Following Gileads' takeover of Kite and the approval of Kymriah, interest in CAR-T & gene therapy companies has soared in the US and I am sure Nightstar is right in taking advantage of this for an IPO as soon as possible. Of course, as with all biotech mergers, the egos would have to fit in with the transaction but, on the surface at least, it would seem to make sense. Does anyone agree?

Trouble_Two 07 Sep 2017

Thanks OXB A profit is a profit. I wish this company all the luck in the future (especially after BRITEXIT) and I hope that they will make a success. For me the fundamentals are far to risky now. Any glitch and this share will dive faster than a space shuttle in space...............my view.As always GL to all holdersTT

Trouble_Two 07 Sep 2017

Sell: Bearish Charts ALL BEARISH06 Sep 2017DAILY8.97Price Crosses Moving Average (21-day) 06 Sep 2017DAILY8.97Moving Average Convergence/Divergence (MACD) 05 Sep 2017DAILY9.04Commodity Channel Index (CCI)04 Sep 2017DAILY9.37Williams %R But as always DYOR and you decideTTI will be back around 6p.

d gaser 05 Sep 2017

Re: Best news and share down 20% Trouble -Two in answer to your question a seller or a buyer cane sell into the market at an agreed price with an M/M ,but in order to keep the share price steady, the M/M can then sell those the shares back into the market over a period of time , this is done in order not to spook the market in that stock.The M/M would then report the sell once the holding had been released in full .The problem here I believe, may lay in the fact it was a non executive member of the board wanting to sell at that particular time leading up to financial dates and could be construed as bad timing .Obviously there are rules relating to such a sale which are set by the London Stock exchange, so the date of that sale may have some thing to do with that, especially as the sale was close to OXB half year accounts ,and the date of the FDA decision on the CTL109,what ever the reason, it will have been above board, as the M/M would have been in control of such a large sale of OXB stock . What I found interesting about the 3 transactions ,was the fact he brought back 320,000 shares at a reduced price against the sell, after he had sold 300,000, doe's that indicate that Martin had to take a profit for personal reason which is allowed, but then after selling, he realised he had sold to many shares so reinvested the excess cash back into OXB again ,if that's so, then it shows Martin and Vulpe's still have confidence in the stock in the future to make them more money through OXB growth potential .P.D.Y.H BE HAPPYDAVE